Viking stock fluctuates amid manufacturing concerns with obesity pill
Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.
Viking Therapeutics' Hot Stock Slips After Latest Obesity Drug Trial Results
Viking Therapeutics shares rose Monday morning before reversing course and declining after reporting the latest results from clinical trials of its weight loss drugs.
Viking Therapeutics' Reveals Early-Stage From Experimental Oral Obesity Drug Showing Weight Loss And Safety
Viking Therapeutics highlights VK2735's promising weight loss data at ObesityWeek 2024, with up to 14.7% reduction and improved prediabetic outcomes.
Viking Therapeutics Stock Swings Wildly After Weight-Loss Drug Data
Viking Therapeutics stock is volatile Monday after the pharma company released positive data for its weight-loss drug. Here's what you need to know.
Viking Touts Promising Phase I Weight Loss Data for Obesity Pill Candidate
Jefferies analyst Roger Song in an investor note said that Viking Therapeutics’ readout for its investigational therapy VK2735 exceeded expectations, with “class-leading” weight loss. Patients on 100-miligram doses of the pill lost 8.
Viking Therapeutics Stock Climbs On Positive Data From VK2735 Obesity Program
Shares of Viking Therapeutics, Inc. (VKTX) were gaining around 17 percent in the pre-market activity on the Nasdaq after the company
Viking slips as manufacturing concerns cloud promising oral obesity drug data
By Sriparna Roy and Bhanvi Satija (Reuters) -Viking Therapeutics shares reversed course to fall 8% on Monday as focus shifted to the drug developer's ability to mass produce its oral obesity treatment that was shown to be safe and effective in a small trial.
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
The stock, which enjoys the unusual position of having all buy ratings from the 13 analysts offering coverage on FactSet, has been on a tear this year, gaining 270% to date in 2024.
Viking Therapeutics’ Promising Results for Obesity Treatment
Viking Therapeutics ( (VKTX) ) just unveiled an announcement. Viking Therapeutics has presented promising data from its VK2735 obesity program
Viking Obesity Pill Data Shows Promise Against Shots
Yes, a Viking drug So it's a dual agonist of oral gel or an oral drug, GLP one and GLP essentially targeting two receptors. And yeah, I guess it was one of the most eagerly awaited kind of data set that was conference on that.
Viking rises after 'competitive' efficacy, safety data from oral weight-loss drug
(Reuters) -Viking Therapeutics shares climbed 9% on Monday after the drug developer's oral obesity treatment helped reduce body weight with mild side effects in a small trial, data that analysts said compared favorably to some rivals in development.
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...
The Motley Fool on MSN23h
Is Viking Therepautics a Buy Now?
Wall Street's been pounding the table on Viking Therapeutics because VK2735 could become the next and best dual ...
Viking Therapeutics Offers An Obesity Drug for Healthy Adults
Here are the key points about Viking Therapeutics' oral obesity drug VK2735: Early-Stage Trial Results: All doses of VK2735 ...
Wall Street Lunch: Viking Weight-Loss Pill Data Is Striking
Viking Therapeutics shares surge as VK2735 shows significant weight loss in early-stage study, with plans for a phase 2 ...
Promising Phase 1 Results for Viking Therapeutics’ VK2735: Analyst Recommends Buy Rating
Michael Ulz, an analyst from Morgan Stanley, reiterated the Buy rating on Viking Therapeutics (VKTX – Research Report). The associated ...
Why Viking Therapeutics Stock Plummeted After Soaring Today
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...